CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
15.980
1.11%
Market Trading Hours* (UTC) Opens on Monday at 07:00

Mon - Fri: 07:00 - 11:00 11:03 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.045
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.02529 %
Charges from full value of position ($-4.81)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02529%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003373 %
Charges from full value of position ($0.64)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003373%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency GBP
Margin 5%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

*Information provided by Capital.com

GSK plc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 15.805
Open* 15.74
1-Year Change* 6.14%
Day's Range* 15.735 - 15.98
52 wk Range 13.03-15.99
Average Volume (10 days) 8.17M
Average Volume (3 months) 143.07M
Market Cap 64.01B
P/E Ratio 10.48
Shares Outstanding 4.12B
Revenue 29.65B
EPS 1.48
Dividend (Yield %) 3.58383
Beta 0.55
Next Earnings Date Jan 31, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 15.980 0.225 1.43% 15.755 15.980 15.725
Apr 18, 2024 15.805 -0.090 -0.57% 15.895 15.935 15.775
Apr 17, 2024 15.770 -0.145 -0.91% 15.915 15.985 15.740
Apr 16, 2024 16.060 -0.160 -0.99% 16.220 16.240 15.910
Apr 15, 2024 16.390 0.110 0.68% 16.280 16.450 16.280
Apr 12, 2024 16.410 0.115 0.71% 16.295 16.495 16.230
Apr 11, 2024 16.260 0.100 0.62% 16.160 16.395 16.150
Apr 10, 2024 16.160 -0.025 -0.15% 16.185 16.245 16.015
Apr 9, 2024 16.090 0.000 0.00% 16.090 16.150 16.010
Apr 8, 2024 16.155 -0.065 -0.40% 16.220 16.255 16.130
Apr 5, 2024 16.235 0.210 1.31% 16.025 16.265 15.885
Apr 4, 2024 16.290 -0.220 -1.33% 16.510 16.685 16.290
Apr 3, 2024 16.480 -0.105 -0.63% 16.585 16.620 16.380
Apr 2, 2024 16.340 -0.245 -1.48% 16.585 16.895 16.340
Mar 28, 2024 16.910 0.010 0.06% 16.900 17.105 16.900
Mar 27, 2024 17.000 0.040 0.24% 16.960 17.025 16.775
Mar 26, 2024 16.945 0.300 1.80% 16.645 16.985 16.645
Mar 25, 2024 16.905 0.115 0.68% 16.790 16.920 16.770
Mar 22, 2024 16.855 0.095 0.57% 16.760 16.920 16.715
Mar 21, 2024 16.660 0.280 1.71% 16.380 16.795 16.325

GlaxoSmithKline PLC Events

Time (UTC) Country Event
Wednesday, May 1, 2024

Time (UTC)

10:59

Country

GB

Event

Q1 2024 GSK plc Earnings Release
Q1 2024 GSK plc Earnings Release

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

13:30

Country

GB

Event

GSK plc Annual Shareholders Meeting
GSK plc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, May 8, 2024

Time (UTC)

13:30

Country

GB

Event

GSK plc Annual Shareholders Meeting
GSK plc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, July 31, 2024

Time (UTC)

10:59

Country

GB

Event

Q2 2024 GSK plc Earnings Release
Q2 2024 GSK plc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 29324 24696 24354 33754 30821
Revenue 29324 24696 24354 33754 30821
Cost of Revenue, Total 8467 8006 7321 10168 9572
Gross Profit 20857 16690 17033 23586 21249
Total Operating Expense 22891 20375 18375 26793 25335
Selling/General/Admin. Expenses, Total 8128 6749 7025 10671 9408
Research & Development 5062 4525 4322 4338 3726
Depreciation / Amortization 91 101 75 64 44
Interest Expense (Income) - Net Operating 1433 1073 1220 -128 1839
Unusual Expense (Income) 529 355 -1205 2051 1038
Other Operating Expenses, Total -819 -434 -383 -371 -292
Operating Income 6433 4321 5979 6961 5486
Interest Income (Expense), Net Non-Operating -6 -1283 -400 -708 -602
Other, Net -799 561 -409 -32 -84
Net Income Before Taxes 5628 3599 5170 6221 4800
Net Income After Taxes 4921 3516 5103 5268 3921
Minority Interest -665 -711 -639 -623 -423
Net Income Before Extra. Items 4256 2805 4464 4645 3498
Net Income 14956 4385 5749 4645 3623
Income Available to Common Excl. Extra. Items 4256 2805 4464 4645 3498
Income Available to Common Incl. Extra. Items 14956 4385 5749 4645 3623
Dilution Adjustment
Diluted Net Income 14956 4385 5749 4645 3623
Diluted Weighted Average Shares 4084 4052 4030 4012.8 3976.8
Diluted EPS Excluding Extraordinary Items 1.04212 0.69225 1.10769 1.15755 0.8796
Dividends per Share - Common Stock Primary Issue 0.6125 1 1 1 1
Diluted Normalized EPS 1.14153 0.6809 0.78859 1.69458 1.0682
Total Extraordinary Items 10700 1580 1285 125
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 7178 6951 7376 7829 6929
Revenue 7178 6951 7376 7829 6929
Cost of Revenue, Total 1892 1903 2177 2386 2136
Gross Profit 5286 5048 5199 5443 4793
Total Operating Expense 5037 4868 5508 6638 5848
Selling/General/Admin. Expenses, Total 2191 2065 2435 1968 1955
Research & Development 1315 1222 1522 1297 1155
Depreciation / Amortization 20 18 16 26 26
Unusual Expense (Income) -155 -160 -436 1216 735
Other Operating Expenses, Total -226 -180 -206 -255 -159
Operating Income 2141 2083 1868 1191 1081
Interest Income (Expense), Net Non-Operating -154 -176 -242 -179 -185
Net Income Before Taxes 1987 1907 1626 1012 896
Net Income After Taxes 1745 1631 1625 779 746
Minority Interest -121 -141 -125 -38 -137
Net Income Before Extra. Items 1624 1490 1500 741 609
Net Income 1624 1490 2001 10315 838
Income Available to Common Excl. Extra. Items 1624 1490 1500 741 609
Income Available to Common Incl. Extra. Items 1624 1490 2001 10315 838
Dilution Adjustment
Diluted Net Income 1624 1490 2001 10315 838
Diluted Weighted Average Shares 4093 4082.19 4087.34 4088.39 3220
Diluted EPS Excluding Extraordinary Items 0.39677 0.365 0.36699 0.18125 0.18913
Dividends per Share - Common Stock Primary Issue 0.14 0.14 0.1375 0.1375 0.1625
Diluted Normalized EPS 0.37674 0.31919 0.25811 0.43734 0.37795
Total Extraordinary Items 0 501 9574 229
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 20769 18674 20247 19491 16927
Cash and Short Term Investments 7877 4335 6370 4786 3958
Cash 879 1427 1762 795 569
Short Term Investments 6998 2908 4608 3991 3389
Total Receivables, Net 7115 8031 7264 7148 6322
Accounts Receivable - Trade, Net 5471 6258 5562 5494 5185
Total Inventory 5146 5783 5996 5947 5476
Prepaid Expenses 343 315 359 316 330
Other Current Assets, Total 288 210 258 1294 841
Total Assets 60146 79103 80431 79692 58066
Property/Plant/Equipment, Total - Net 9620 10672 11006 11314 11058
Property/Plant/Equipment, Total - Gross 20138 21518 22313 22565 22488
Accumulated Depreciation, Total -10518 -10846 -11307 -11251 -11430
Goodwill, Net 7046 10552 10597 10562 5789
Intangibles, Net 14318 30079 29824 30955 17202
Long Term Investments 1541 2214 3424 2151 1558
Note Receivable - Long Term 965 935 858 893 816
Other Long Term Assets, Total 5887 5977 4475 4326 4716
Total Current Liabilities 22810 23670 22148 24050 22491
Accounts Payable 3866 4535 4357 4144 3645
Accrued Expenses 10587 11186 9753 9111 8535
Notes Payable/Short Term Debt 1639 802 1145 5020 4420
Current Port. of LT Debt/Capital Leases 2313 2799 2580 1898 1373
Other Current Liabilities, Total 4405 4348 4313 3877 4518
Total Liabilities 49548 64048 65844 68287 53706
Total Long Term Debt 17035 20572 23425 23590 20271
Long Term Debt 16194 19760 22538 22580 20227
Capital Lease Obligations 841 812 887 1010 44
Deferred Income Tax 289 3556 3600 3810 1156
Minority Interest -502 6287 6221 6952 -688
Other Liabilities, Total 9916 9963 10450 9885 10476
Total Equity 10598 15055 14587 11405 4360
Common Stock 1347 1347 1346 1346 1345
Additional Paid-In Capital 3440 3301 3281 3174 3091
Retained Earnings (Accumulated Deficit) 6492 10073 8884 6659 -8
ESOP Debt Guarantee -353 -28 -195 -135 -161
Unrealized Gain (Loss) -308 383 1302 409 140
Other Equity, Total -20 -21 -31 -48 -47
Total Liabilities & Shareholders’ Equity 60146 79103 80431 79692 58066
Total Common Shares Outstanding 4034.34 4025.45 4023.99 3962.58 3938.34
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 21240 19348 19719 20769 20249
Cash and Short Term Investments 6683 6504 6975 7877 7161
Cash & Equivalents 3177 3140 2890 3723 3606
Short Term Investments 3506 3364 4085 4154 3555
Total Receivables, Net 8874 7095 7129 7458 8094
Accounts Receivable - Trade, Net 8544 6776 6833 7053 7508
Total Inventory 5480 5512 5355 5146 4659
Other Current Assets, Total 203 237 260 288 335
Total Assets 60862 59461 58596 60146 60313
Property/Plant/Equipment, Total - Net 9454 9315 9414 9620 9650
Goodwill, Net 6973 6716 6857 7046 7195
Intangibles, Net 15295 15531 14160 14318 15589
Long Term Investments 1142 1350 1340 1541 1630
Other Long Term Assets, Total 6758 7201 7106 6852 6000
Total Current Liabilities 22390 22108 20696 22810 20953
Payable/Accrued 15582 13951 14268 16263 16115
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 4843 5921 4261 3952 2793
Other Current Liabilities, Total 1965 2236 2167 2595 2045
Total Liabilities 47729 46770 46776 49548 51161
Total Long Term Debt 15993 15553 16644 17035 19322
Long Term Debt 15993 15553 16644 17035 19322
Deferred Income Tax 402 500 290 289 364
Minority Interest -514 -532 -508 -502 -436
Other Liabilities, Total 9458 9141 9654 9916 10958
Total Equity 13133 12691 11820 10598 9152
Common Stock 1348 1348 1348 1347 1347
Additional Paid-In Capital 3450 3450 3449 3440 3440
Retained Earnings (Accumulated Deficit) 8335 7893 7023 5811 4365
Total Liabilities & Shareholders’ Equity 60862 59461 58596 60146 60313
Total Common Shares Outstanding 4095.03 4095 4094.95 4034.34 4067.38
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 4921 5096 6388 5268 4046
Cash From Operating Activities 7403 7952 8441 8020 8421
Cash From Operating Activities 1061 1195 1214 1231 954
Amortization 1086 1182 1137 1103 902
Non-Cash Items 2433 1252 -332 2355 1344
Cash Taxes Paid 1310 1291 1655 1512 1326
Cash Interest Paid 848 786 864 895 766
Changes in Working Capital -2098 -773 34 -1937 1175
Cash From Investing Activities -8772 -1777 2161 -5354 -1553
Capital Expenditures -2258 -2931 -2239 -2163 -1796
Other Investing Cash Flow Items, Total -6514 1154 4400 -3191 243
Cash From Financing Activities 823 -7589 -10132 -1840 -6389
Financing Cash Flow Items 9089 -1401 -1950 -1453 -10660
Total Cash Dividends Paid -3467 -3999 -3977 -3953 -3927
Issuance (Retirement) of Stock, Net 25 21 29 51 74
Issuance (Retirement) of Debt, Net -4824 -2210 -4234 3515 8124
Foreign Exchange Effects 152 -29 -39 -82 8
Net Change in Cash -394 -1443 431 744 487
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 1631 4921 3296 2517 2167
Cash From Operating Activities 53 7403 5498 4177 2542
Cash From Operating Activities 640 2299 2291 1335 704
Non-Cash Items 451 2281 2034 1632 634
Cash Taxes Paid 234 1310 1110 534 213
Cash Interest Paid 120 848 504 437 85
Changes in Working Capital -2669 -2098 -2123 -1307 -963
Cash From Investing Activities -408 -8772 -8232 -4138 -3593
Capital Expenditures -529 -2258 -1507 -1027 -601
Other Investing Cash Flow Items, Total 121 -6514 -6725 -3111 -2992
Cash From Financing Activities -318 823 2161 3487 7973
Financing Cash Flow Items -130 9089 9314 8742 16
Total Cash Dividends Paid -555 -3467 -2813 -2108 -952
Issuance (Retirement) of Stock, Net 6 25 25 17 12
Issuance (Retirement) of Debt, Net 361 -4824 -4365 -3164 8897
Foreign Exchange Effects -31 152 106 83 12
Net Change in Cash -704 -394 -467 3609 6934

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

GSK Company profile

GlaxoSmithKline PLC - GSK CFD

GlaxoSmithKline (GSK) is a global healthcare company focussed in pharmaceuticals, vaccine development and consumer healthcare products. 

The company began as an apothecary shop in London in 1715. Today, GlaxoSmithKline is headquartered in Brentford, England, with regional offices in the US and Singapore. GlaxoSmithKline’s primary listing is on the London Stock Exchange under the ticker symbol ‘GSK’. The GSK stock price in the form of  American depositary shares is listed on the New York Stock Exchange.   

GlaxoSmithKline’s pharmaceutical business covers a broad portfolio of medicines in respiratory, HIV, immuno-inflammation and oncology. The company has a leadership position in respiratory disease medicines. GlaxoSmithKline’s HIV business is managed through its unit ViiV Healthcare, with Pfizer and Shionogi as minority shareholders. 

In addition to respiratory and HIV treatments, the company has a portfolio of pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives. 

Its Established Products Portfolio (EPP) includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business.

GlaxoSmithKline is actively researching the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.

GlaxoSmithKline is also one of the world’s largest vaccine companies with a portfolio of more than 20 vaccines. The company has 12 vaccine manufacturing sites around the world. One of its four global R&D centres is dedicated to mRNA technology.

GlaxoSmithKline’s consumer healthcare business has portfolio of brands that include Sensodyne, Parodontax, Polident, Advil, Voltaire, Panadol, Striven, Theraflu and Centrum across oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, mineral and supplements segments. GlaxoSmithKline is set to spin-off its consumer healthcare business into an independent company under the name ‘Haleon’.’

The company pays dividends on a quarterly basis, in July, October, January and April.
Follow the GlaxoSmithKline stock price live at Capital.com today.

Industry: Pharmaceuticals (NEC)

980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.52 Price
+2.570% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

64,050.25 Price
-0.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading